Analysts Set Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Price Target at $28.14

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have been given an average rating of “Hold” by the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $28.1429.

A number of equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. initiated coverage on shares of Kestra Medical Technologies in a research note on Monday, August 10th. They set an “overweight” rating and a $30.00 price objective on the stock. Wall Street Zen lowered shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating on the stock. BTIG Research reissued a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a report on Wednesday, September 2nd. Finally, Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th.

Kestra Medical Technologies News Summary

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra appointed Daniel Finney as Vice President of Research & Development and added him to its executive leadership team. Finney has more than 20 years of Class III medical-device experience and previously led Kestra’s new product development. He will oversee innovation for the Cardiac Recovery System, including strategic partnerships and artificial-intelligence initiatives, providing leadership continuity after the retirement of Phillip Foshee. Kestra Names Daniel Finney Vice President of Research & Development
• Neutral Sentiment: Reported short interest was zero shares as of September 10, unchanged from the prior reporting period. This suggests limited measurable short-selling pressure, but also provides little new information for investors.
• Neutral Sentiment: Analyst expectations remain mixed. BTIG maintains a $32 price target and JPMorgan has a $30 target, while other analysts are more cautious; the reported median target from recent forecasts is $24.50. The upcoming earnings release could prompt additional estimate changes. Kestra earnings preview
• Negative Sentiment: Four directors sold a combined 16,424 shares worth approximately $414,000. The transactions reduced their individual holdings by about 9% to 48%. Because the sales were made to cover tax withholding on vested equity awards, they are less concerning than discretionary selling, though the cluster may weigh on sentiment. SEC insider transaction filings
• Negative Sentiment: Kestra is expected to report a first-quarter loss, adding to concerns about profitability. Its latest reported quarter showed a $0.67 per-share loss, worse than the $0.59 consensus estimate, despite revenue of $28.64 million. Analysts currently forecast a full-year loss of approximately $2.29 per share.

Kestra Medical Technologies Trading Down 3.1%

NASDAQ KMTS opened at $22.85 on Monday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. Kestra Medical Technologies has a one year low of $17.34 and a one year high of $30.00. The company has a 50-day simple moving average of $25.34 and a 200-day simple moving average of $22.71. The firm has a market capitalization of $1.34 billion, a PE ratio of -9.44 and a beta of 0.62.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The company had revenue of $28.64 million for the quarter. On average, equities analysts forecast that Kestra Medical Technologies will post -2.29 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Mary Ladone sold 3,908 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $25.20, for a total value of $98,481.60. Following the completion of the sale, the director owned 37,507 shares in the company, valued at $945,176.40. This represents a 9.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Brian Webster sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $27.48, for a total value of $412,200.00. Following the transaction, the insider directly owned 460,215 shares of the company’s stock, valued at $12,646,708.20. This represents a 3.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 254,588 shares of company stock worth $6,114,838. 5.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of KMTS. Farther Finance Advisors LLC purchased a new position in Kestra Medical Technologies during the 4th quarter valued at about $31,000. Russell Investments Group Ltd. grew its holdings in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after buying an additional 474 shares during the last quarter. BNP Paribas Financial Markets grew its position in Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after buying an additional 1,638 shares in the last quarter. Daiwa Securities Group Inc. acquired a new stake in Kestra Medical Technologies during the fourth quarter worth $72,000. Finally, Brown Brothers Harriman & Co. increased its stake in Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares during the period.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.